Use of tryptophan derivatives for protein formulations

Patent metadata

Field	Value
Publication number	US-2017239355-A1
Application number	US-201615393143-A
Country	US
Kind code	A1
Filing date	Dec 28, 2016
Priority date	Dec 30, 2015
Publication date	Aug 24, 2017
Grant date	—

Abstract

The invention provides methods and formulations comprising a protein comprising solvent accessible amino acid residues susceptible to oxidation wherein N-acetyl tryptophan (NAT) is used to prevent oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. Methods to measure degradation of NAT in protein formulations are also provided.

First claim

1 . A method of reducing oxidation of a polypeptide in an aqueous formulation comprising adding an amount of N-acetyltryptophan to the formulation that prevents oxidation of the polypeptide, wherein the polypeptide comprises at least one tryptophan residue with a solvent-accessible surface area (SASA) of greater than about 80 Å 2 .

2 . A method of reducing oxidation of a polypeptide in an aqueous formulation comprising adding an amount of N-acetyltryptophan to the formulation that prevents oxidation of the polypeptide, wherein the polypeptide comprises at least one tryptophan residue with a solvent-accessible surface area (SASA) of greater than about 30%.

3 . A method of reducing oxidation of a polypeptide in an aqueous formulation comprising determining the SASA values of tryptophan residues in the polypeptide and adding an amount of N-acetyltryptophan to the formulation that prevents oxidation of the polypeptide if at least one tryptophan residue has a solvent-accessible surface area (SASA) of greater than about 80 Å 2 .

4 . The method of claim 3 , wherein the SASA value of the tryptophan residues in calculated by molecular dynamic simulation.

5 . The method of claim 1 , wherein the N-acetyltryptophan is added to the formulation to a concentration of about 0.1 mM to about 5 mM, about 0.1 mM to about 1 mM, or about 0.3 mM.

6 - 7 . (canceled)

8 . The method of claim 1 , wherein the oxidation of the polypeptide is reduced by about 50%, 75%, 80%, 85%, 90%, 95% or 99%.

9 . The method of claim 1 , wherein the formulation is stable at about 2° C. to about 8° C. for about 1095 days.

10 . The method of claim 1 , wherein the protein concentration in the formulation is about 1 mg/mL to about 250 mg/mL.

11 . The method of claim 1 , wherein the formulation has a pH of about 4.5 to about 7.0.

12 . The method of claim 1 , wherein the formulation further comprises one or more excipients selected from the group consisting of a stabilizer, a buffer, a surfactant, and a tonicity agent.

13 . The method of claim 1 , wherein the formulation is a pharmaceutical formulation suitable for administration to a subject.

14 . (canceled)

15 . The method of claim 1 , wherein the protein is a polyclonal antibody, a monoclonal antibody, a humanized antibody, a human antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment.

16 . A liquid formulation comprising a polypeptide and an amount of N-acetyltryptophan to prevent oxidation of the polypeptide, wherein the polypeptide has at least one tryptophan residue with a SASA of greater than about 80 Å 2 .

17 . The liquid formulation of claim 16 , wherein the N-acetyltryptophan is added to the formulation to a concentration of about 0.1 mM to about 5 mM, about 0.1 mM to about 1 mM, or about 0.3 mM.

18 - 19 . (canceled)

20 . The liquid formulation of claim 16 , wherein the oxidation of the polypeptide is reduced by about 50%, 75%, 80%, 85%, 90%, 95% or 99%.

21 . The liquid formulation of claim 16 , wherein the formulation is stable at about 2° C. to about 8° C. for about 1065 days.

22 . The liquid formulation of claim 16 , wherein the protein concentration in the formulation is about 1 mg/mL to about 250 mg/mL.

23 . The liquid formulation of claim 16 , wherein the formulation has a pH of about 4.5 to about 7.0.

24 . The liquid formulation of claim 16 , wherein the formulation further comprises one or more excipients selected from the group consisting of a stabilizer, a buffer, a surfactant, and a tonicity agent.

25 . The liquid formulation of claim 16 , wherein the formulation is a pharmaceutical formulation suitable for administration to a subject.

26 . (canceled)

27 . The liquid formulation of claim 16 , wherein the protein is a polyclonal antibody, a monoclonal antibody, a humanized antibody, a human antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment.

28 . A method for screening a formulation for reduced oxidation of a polypeptide wherein the polypeptide comprises at least one tryptophan residue with a SASA of greater than about 80 Å 2 , the method comprising
adding an amount of N-acetyltryptophan to an aqueous composition comprising the polypeptide,
adding 2,2′-azobis (2-aminopropane) dihydrochloride (AAPH) to the composition,
incubating the composition comprising the polypeptide, N-acetyltryptophan and AAPH for about 14 hours at about 40° C.,
measuring the polypeptide for oxidation of tryptophan residues in the polypeptide,
wherein a formulation comprising an amount of N-acetyltryptophan that results in no more than about 20% oxidation of tryptophan residues of the polypeptide is a suitable formulation for reduced oxidation of the polypeptide.

29 . A method for screening a formulation for reduced oxidation of a polypeptide comprising
determining the SASA values of tryptophan residues in the polypeptide, wherein a tryptophan residue with a SASA of greater than about 80 Å 2 , is subject to oxidation, adding an amount of N-acetyltryptophan to an aqueous composition comprising the polypeptide, adding 2,2′-azobis (2-aminopropane) dihydrochloride (AAPH) to the composition, incubating the composition comprising the polypeptide, N-acetyltryptophan and AAPH for about 14 hours at about 40° C., measuring the polypeptide for oxidation of tryptophan residues in the polypeptide, wherein a formulation comprising an amount of N-acetyltryptophan that results in no more than about 20% oxidation of tryptophan residues of the polypeptide is a suitable formulation for reduced oxidation of the polypeptide.

30 . The method of claim 29 , wherein the SASA value of the tryptophan residues in calculated by molecular dynamic simulation.

31 . A kit comprising the liquid formulation of claim 16 .

32 . An article of manufacture comprising the liquid formulation of claim 16 .

33 . A method to determine if a polypeptide in a liquid formulation comprises a tryptophan residue susceptible to oxidation, the method comprising calculating one or more molecule descriptors based on the amino acid sequence of the polypeptide for each tryptophan residue in the polypeptide and applying the one or more molecule descriptors to a machine learning algorithm trained on the one or more molecule descriptors to predict tryptophan oxidation, wherein the molecule descriptors include one or more of the following:
a) number of aspartic acid sidechain oxygens within 7 Å of tryptophan delta carbon, b) sidechain solvent accessible surface area (SASA), c) delta carbon SASA, d) total positive charge within 7 Å of tryptophan delta carbon, e) backbone SASA, f) tryptophan sidechain angles, g) packing density within 7 Å of tryptophan delta carbon, h) tryptophan backbone angles, i) SASA of pseudo-pi orbitals, j) backbone flexibility, or k) total negative charge within 7 Å of tryptophan delta carbon.

34 - 40 . (canceled)

41 . A method to reduce oxidation of a polypeptide, comprising identifying tryptophan residues susceptible to oxidation according to the method of claim 33 and introducing an amino acid substitution in the polypeptide to replace one or more tryptophan residues susceptible to oxidation with amino acid residues that are not subject to oxidation.

42 -

Assignees

• Genentech Inc

Inventors

• Sharma Vikas
• Leiske Danielle
• Hamburg Lydia
• Salisbury Cleo

Classifications

• G01N2030/884

  organic compounds · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title

• G06F19/24

  Physics · mapped topic

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• G01N33/6812

  Assays for specific amino acids · CPC title